# Test Summary: TC_P1_PATIENT_001_Normal.vcf

## Patient Assessment

- **Patient ID**: 5afccaef-7f27-4c8b-891d-b0eb437fefa6
- **Overall Risk Score**: 15
- **High Risk Variants Count**: 0
- **Summary**: No high-risk variants identified.

## Pharmacogenomic Profile

| Gene    | Variant     | Genotype | Phenotype          | Confidence |
| ------- | ----------- | -------- | ------------------ | ---------- |
| CYP2D6  | rs3892097   | *1/*1    | Normal Metabolizer | 99%        |
| CYP2C19 | rs12248560  | *1/*1    | Normal Metabolizer | 98%        |
| CYP2C9  | rs1799853   | *1/*1    | Normal Metabolizer | 97%        |
| SLCO1B1 | rs4149056   | *1/*1    | Normal Function    | 96%        |
| DPYD    | rs3918290   | *1/*1    | Normal Metabolizer | 99%        |
| TPMT    | rs1142345   | *1/*1    | Normal Metabolizer | 99%        |
| VKORC1  | rs9923231   | *1/*1    | Normal Sensitivity | 99%        |
| NUDT15  | rs116855232 | *1/*1    | Normal Metabolizer | 99%        |
| CYP4F2  | rs2108622   | *1/*1    | Normal Metabolizer | 97%        |

## Clinical Recommendations

- **Standard Medications**: Standard Dosage (No high-risk genetic variants detected for primary metabolic pathways.)

## AI Clinical Explanations

- **Biological Explanation**: Found significant metabolic variations in the pathway(s). Specifically, the primary gene is behaving as a standard metabolizer.
- **Clinical Interpretation**: Based on processed PharmGKB and CPIC datasets, clinical actions are warranted for specific prodrugs or substances if relevant.
- **Evidence Citation**: CPIC Guidelines v4.2; FDA/EMA Drug Labels 2026.

## Quality Metrics

- **Variant Evidence**: 1A
- **Annotation Quality**: High (ClinPGx Integrated)
- **Database Certainty**: 99.4%
